Pharmacists in Oneida, WI Accepting Medicare
6 Pharmacists found. Showing 1 - 6
 Stacey J Weise, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1470 Larkspur Ln, Oneida, WI 54155 Phone: 920-660-8153 |
Sarah Dykstra Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 525 Airport Dr, Oneida, WI 54155 Phone: 920-869-4826 Fax: 920-869-1785 |
Mary C Lamers, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 525 Airport Dr, Oneida, WI 54155 Phone: 920-869-4826 |
 Mr. James R. Poels, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 525 Airport Dr, Oneida, WI 54155 Phone: 920-869-2711 Fax: 920-869-1785 |
James Robert Ray Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 525 Airport Dr, Oneida, WI 54155 Phone: 920-869-4826 |
John R. Badtke, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 525 Airport Dr, Oneida, WI 54155 Phone: 920-869-4826 Fax: 920-869-1785 |
News Archive
Staged surgery for most complex cases of childhood epilepsy
A staged approach to epilepsy surgery-with invasive brain monitoring followed by surgery in a single hospital stay-is a safe and beneficial approach to treatment for complex cases of epilepsy in children, reports the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
Tracking early signs of coronary artery clogs: CT perfusion vs. SPECT nuclear imaging tests
Cardiologists and heart imaging specialists at 15 medical centers in eight countries, and led by researchers at Johns Hopkins, have enrolled the first dozen patients in a year-long investigation to learn whether the subtle squeezing of blood flow through the inner layers of the heart is better than traditional SPECT nuclear imaging tests and other diagnostic radiology procedures for accurately tracking the earliest signs of coronary artery clogs.
Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
First license to begin research involving therapeutic cloning
A special licensing committee of the UK Human Fertilization & Embryology Authority (HFEA) met on June 16 in London to decide whether to grant a license to scientists at The Center for Life at Newcastle University.
› Verified 7 days ago